In This Section      

Ciccarone Articles

Ciccarone Center Research


ASCVD (Atherosclerotic Cardiovascular Disease)

Landmark Articles

Modifiable lifestyle risks, cardiovascular disease, and all-cause mortality.
By: Ahmed HM, Blaha MJ, Blumenthal RS.
Read on Pubmed
C-reactive protein is independently associated with coronary atherosclerosis burden among octogenarians.
By: Quaglia LA, Freitas WM, Soares AA, Santos RD, Nadruz W, Blaha MJ, Coelho OR, Blumenthal R, Agatston A, Nasir K, Sposito AC.
We examined measures of inflammation and subclinical atherosclerosis in persons with successful cardiovascular aging.
Read on Pubmed
Family history of coronary heart disease and the incidence and progression of coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA).
By: Pandey AK, Blaha MJ, Sharma K, Rivera J, Budoff MJ, Blankstein R, Al-Mallah M, Wong ND, Shaw L, Carr J, O’Leary D, Lima JA, Szklo M, Blumenthal RS, Nasir K.

A multiethnic, population-based study showed that a family history of premature CHD is associated with enhanced development and progression of subclinical disease, independent of other risk factors.

Read on Pubmed
Short and lifetime cardiovascular risk estimates: same wine, different bottles. Do we have the COURAGE to abandon risk scores?
By: Nasir K, Blaha MJ.
This editorial examines the shortcomings of traditional cardiovascular risk assessment scores.
Read on Pubmed
Exercise and physical activity for cardiovascular disease prevention.
By: Ahmed H, Ndumele CE.
Polypill therapy, subclinical atherosclerosis, and cardiovascular events — implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis).
By: Bittencourt MS, Blaha MJ, Blankstein R, Budoff M, Vargas JD, Blumenthal RS, Agatston AS, Nasir K.
The authors conclude that avoidance of polypill therapy in individuals with subclinical atherosclerosis could allow for a more selective use of the treatment and, as a result, avoidance of treatment in those who are unlikely to benefit.
Read on Pubmed
All-cause mortality in asymptomatic persons with extensive Agatston scores above 1000.
By: Patel J, Blaha MJ, McEvoy JW, Qadir S, Tota-Maharaj R, Shaw LJ, Rumberger JA, Callister TQ, Berman DS, Min JK, Raggi P, Agatston AA, Blumenthal RS, Budoff MJ, Nasir K.
Increasing calcified plaque in coronary arteries continues to predict a graded decrease in survival among patients with extensive Agatston score > 1000 with no apparent upper threshold.
Read on Pubmed
Heart disease and stroke statistics — 2014 update: a report from the American Heart Association.
By: Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
Read on Pubmed
Peripheral Artery Disease.
By: Salameh MJ, Ratchford EV.
Development of a center for prevention of cardiovascular disease.
By: Ashen MD, Nell-Dybdahl CL, Sperling L, Blumenthal RS.
We discuss the key components of various types of preventive cardiology centers that can be put together in academic and private practice settings.